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Abstract 
Background: Human African trypanosomiasis (HAT) is a protozoal 
disease transmitted by tsetse flies. Infection with trypanosomes can 
lead directly to active HAT or latent infection with no detectable 
parasites, which may progress to active HAT or to spontaneous self-
cure. Genetic variation could explain these differences in the outcome 
of infection. To test this hypothesis, polymorphisms in 17 candidate 
genes were tested (APOL1 [G1 and G2], CFH, HLA-A, HPR, HP, IL1B, IL12B, 
IL12RB1, IL10, IL4R, MIF, TNFA, IL6, IL4, IL8, IFNG, and HLA-G). 
Methods: Samples were collected in Democratic Republic of the 
Congo. 233 samples were genotyped: 100 active HAT cases, 33 from 
subjects with latent infections and 100 negative controls. Commercial 
service providers genotyped polymorphisms at 96 single nucleotide 
polymorphisms (SNPs) on 17 genes. Data were analyzed using Plink 
V1.9 software and R. Loci, with suggestive associations (uncorrected p 
< 0.05) validated using an additional 594 individuals, including 164 
cases and 430 controls. 
Results: After quality control, 87 SNPs remained in the analysis. Two 
SNPs in IL4 and two in IFNG were suggestively associated (uncorrected 
p<0.05) with a differential risk of developing a Trypanosoma brucei 
gambiense infection in the Congolese population. The IFNG minor 
allele (rs2430561, rs2069718) SNPs were protective in comparison 
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between latent infections and controls. Carriers of the rs2243258_T 
and rs2243279_A alleles of IL4 and the rs2069728_T allele of IFNG had 
a reduced risk of developing illness or latent infection, respectively. 
None of these associations were significant after Bonferroni 
correction for multiple testing. A validation study using more samples 
was run to determine if the absence of significant association was due 
to lack of power. 
Conclusions: This study showed no evidence of an association of HAT 
with IL4 and IFNG SNPs or with APOL1 G1 and G2 alleles, which have 
been found to be protective in other studies.
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Introduction
Human African trypanosomiasis (HAT), or sleeping sickness, 
is a neglected tropical disease caused by infection with extracel-
lular blood protozoan parasites, which are transmitted by the bite 
of the tsetse fly (Glossina sp) (Headrick, 2014).
The disease is present in more than 250 foci in Africa and 
nearly 70 million people are at risk of infection with the two 
human-infective forms. A chronic form is found in Central and 
Western Africa and is caused by Trypanosoma brucei gambiense 
(Tbg); an acute form is caused by Trypanosoma brucei rhode-
siense (Tbr) and is found in East Africa. About 97% of all HAT 
cases are due to Tbg infection, which causes a chronic disease 
with a long latency period (Kennedy, 2013).
There is currently no vaccine against HAT. The control of 
Tbg HAT is mainly based on the active detection of infected 
cases followed by their treatment and also vector control. After 
infection, the parasites may be undetectable by microscopy 
for months or years; these cases are known as latent infections 
and are detected by serology. Active HAT with microscopically 
detectable parasites evolves in two successive stages: stage 
1 (haemolymphatic) and stage 2 (meningoencephalitis, also 
known as neurological). The transition from stage 1 to stage 2 is 
a consequence of the parasites crossing the blood-brain barrier. 
For a long time, HAT was considered fatal if untreated; 
however, the dogma that HAT is 100% fatal has been ques-
tioned (Jamonneau et al., 2012). It is now recognised that some 
individuals self-cure after developing a latent infection.
The Democratic Republic of the Congo (DRC) is the country 
with the highest incidence of HAT. More than half of districts 
are endemic for HAT, with more than 36 million people at 
risk (Report of a WHO Expert Committee, 2013). There was 
an increase in the number of new cases at the end of the 
20th century in both rural and urban areas; however, the number 
of cases is currently decreasing, with fewer than 3,000 cases 
detected in 2015 (Büscher et al., 2017).
There are several HAT foci in DRC with very different clinical 
presentations and outcomes, which could be explained by the 
presence of genetically different subpopulations of humans and 
possibly parasites, as well as environmental factors (Kande Betu 
Kumesu, 2012). There is also variation in disease phenotype 
within populations, which may be partly due to individual genetic 
variation.
Several genes have been implicated in the control of other infec-
tious diseases (AIDS, tuberculosis, malaria, etc.), but genetic 
data on HAT are more recent and incomplete. For example, 
differences in cytokine levels and other immunological markers 
may be a consequence of differences in disease states or of 
genetic differences between individuals in these cytokine genes or 
in genes that regulate them.
Polymorphisms in IL6, IL10, IL1A and TNFA have been associ-
ated with risk of developing HAT (Bucheton et al., 2011; Courtin 
et al., 2006; Courtin et al., 2007) in the DRC, although only 
the association with IL6 remained significant after Bonferroni 
correction. An HLA-G haplotype has also been associated with 
HAT susceptibility in a Congolese population (Courtin et al., 
2013).
It has also been reported that levels of interleukins IL8 and 
IL10 increase during infection and then decrease after treat-
ment (Lejon et al., 2002) and that the stages of the disease are 
also correlated with levels of IL6 and IL10 (Ilboudo et al., 2012; 
Sternberg et al., 2005). Our study is designed to investigate 
polymorphisms in candidate genes that have previously been 
implicated in the outcome of HAT, in an active focus in DRC.
Methods
Ethical statement
The study protocol was submitted to the ethics committee of the 
National Ministry of Public Health (DRC) and approved under 
number 1/2013 and by the Ethics Advisory Committee (EACC) 
of the Institute for Research and Development (IRD), Marseille.
All enrolled subjects signed an informed consent form writ-
ten in French which was translated into the local language if 
necessary. Parents or guardians signed consent forms on behalf 
of minors when they couldn’t sign themselves and they had given 
verbal consent.
Study design
This study was one of six studies of populations of HAT endemic 
areas in Guinea, Cameroon, Ivory Coast, DRC, Malawi and 
Uganda (Ahouty et al., 2017; Kabore et al., 2017; Kamoto et al., 
2019; Kimuda et al., 2018; Ofon et al., 2017). The studies were 
designed to have 80% power to detect odds ratios (OR) >2 
for loci with disease allele frequencies of 0.15 – 0.65, with the 
96 single nucleotide polymorphisms (SNPs) genotyped for 
100 cases and 100 controls.
Study site
Our study was conducted in the district of Masi-Manimba, in 
the province of Kwilu, which was formerly a part of Bandundu 
province, in the south-west of the DRC, more than 388 km from 
Kinshasa.
Recruitment
The study was undertaken in two stages: 1) a screen of 96 
candidate loci in 233 subjects and 2) a validation study of two 
loci that were suggestively positive in the first round in 594 
additional subjects.
Subjects were aged at least 12 years old and were enrolled 
in this study from July 2013 to March 2016 during the active 
screening campaigns of the mobile team of the National Program 
of Control of Human African Trypanosomiasis (PNLTHA). 
Participants were recruited in their respective villages during 
active screening campaigns. Simultaneous serological (Card 
Agglutination Test for Trypanosomiasis; CATT) testing and 
parasitological examination were performed. Samples that were 
CATT positive and lymph node fluid or Buffy coat positive for 
trypanosomes by microscopy were subject to the immune 
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trypanolysis test, which is highly specific for T. b. gambiense 
(Van Meirvenne et al., 1995).
The immune trypanolysis test allows to confirm or not the pres-
ence of T. b. gambiense specific antibodies in an individual. 
Individual’s plasma was collected in a 2 ml cryotube in the field, 
kept in a cryocontainer filled with liquid nitrogen and brought to 
the laboratory where plasma was stored in deep freezer -80°c. 
Live particular strains of T. b. gambiense, LiTat 1.3 and LiTat 1.5, 
were incubated with plasma as well as with guinea pig serum, 
serving as a source of complement. If the T. b. gambiense specific 
antibodies are present in the plasma, they bind to trypanosomes 
that will be lysed. Absence of trypanosome mobility, observed 
under a microscope, implied a positive result.
Cases (stages 1 and 2) were recruited from the positive test 
subjects for CATT, for whom parasitological evaluation confirmed 
the presence of the parasites in blood or lymph node fluid (for 
stage 1) and/or cerebrospinal fluid (CSF) (for stage 2).
Controls were CATT negative individuals living in the same 
area as cases and for whom the trypanolysis test was negative.
The subjects with latent infections were individuals who were 
negative by microscopy despite positive CATT and positive 
trypanolysis test results.
Controls and subjects with latent infections were enrolled 
as a comparison group. The first have never been in contact 
with T.b.gambiense , the latter have been in contact with 
T.b.gambiense but in this group, the parasite is no longer found 
in the absence of any treatment.
Individuals who could not provide a sufficient volume of blood 
(less than 9 ml) or were under 12 years old were excluded. 
Previously treated patients were not included as controls.
Sample collection and processing
At inclusion, blood was collected through venepuncture by a 
skilled technician of PNLTHA using two heparin tubes of 5 ml. 
The first tube was used for serological (CATT) and parasitologi-
cal examinations (capillary tube centrifugation [CTC], or mini- 
Anion Exchange Column Trypanosoma on Buffy Coat 
[mAECT-BC]). The second tube was used to collect plasma 
and buffy coat in 2 ml cryotubes. These two last samples were 
taken after centrifugation at 3500 rpm of the blood in the 
heparinized tube for 5 minutes. In addition, if the individual 
had shown enlargement of cervical ganglia, they were punc-
tured and lymph node fluid examined by direct examination for 
trypanosomes. Once the trypanosome was isolated either in 
lymph node fluid or in the blood, the cerebrospinal fluid (CSF) was 
collected by lumbar puncture and examined for stage determina-
tion of the disease according to PNLTHA instructions. Plasma 
and Buffy coat were kept in containers filled with liquid nitrogen 
until they were sent to INRB where plasma was stored in 
the freezer at -20 ° C and Buffy coat in liquid nitrogen for 
subsequent DNA extraction for genotyping. DNA was extracted 
from Buffy Coat using the Maxwell16 Promega kit following 
the manufacturer’s instructions (Maxwell®16 Tissue DNA 
Purification kit, cat# AS1030), quantified by Nanodrop (Thermo 
Scientific Nanodrop 2000, ISOGEN, Life Science) and then 
stored at -20°C. All DNA were sent to Makerere University, 
Uganda where they were quantified by Qubit®3.0 Fluorom-
eter (Invitrogen by Life Technologies) prior to shipment for 
genotyping. DNAs were shipped at room temperature. Transporta-
tion lasted less than 48 hours.
Genotyping
Samples were submitted to Plateforme Genome Transcrip-
tome de Bordeaux at INRA Site de Pierroton. A multiplex assay 
(two sets of 40 SNPs) was designed using Assay Design Suite 
v2.0 (Agena Biosciences). SNP genotyping was achieved with 
the MassArrayiPLEX genotyping assay using the iPLEX Gold 
genotyping kit (Agena Biosciences, cat# 10148-2) described in 
Gabriel et al. (2009). Products were detected on a MassArray 
mass spectrophotometer and data were acquired in real time with 
MassArray RT software 4.0.0.2 (Agena Biosciences). SNP 
clustering and validation was carried out with Typer 4.0.26.75 
software (Agena Biosciences). All monomorphic SNPs and loci 
displaying more than three clusters of genotypes or unclear clus-
ter delimitation were filtered out. 11 SNP that failed genotyp-
ing on the MassArray platform and 16 additional SNPs were 
genotyped by LGC Genomics, Hoddesden, UK (rs1143629, 
rs3212227, rs2546890, rs1130363, rs1233330, rs1818879, 
rs1801275, rs1424241, rs8062041, rs7185840, rs152828, rs375947, 
rs11575934, rs11548056., rs136174, rs73885316, rs136177, 
rs143830837, rs71785313, rs1136754, rs1059563, rs1136903, 
rs1136749, rs2021171) using the PCR-based KASP assay 
(Semagn et al., 2014), as were the SNPs tested in the validation 
study.
SNP selection
SNPs were selected in 17 genes using two strategies. First, SNPs 
that were previously reported to have associations with HAT 
or other infectious diseases were selected in APOL1 (G1 and G2 
SNPs), CFH, HLAA, HPR, HP, IL1B, IL12B, IL12RB1, IL10, 
IL4R, MIF and TNFA (Bucheton et al., 2011; Courtin et al., 2006; 
Genovese et al., 2010; Hardwick et al., 2013; Ilboudo et al., 2012; 
Ilboudo et al., 2014; Jamonneau et al., 2012; Kato et al., 2015; 
MacLean et al., 2004; Sternberg et al., 2005; Stijlemans et al., 
2014).
Second, genome sequence data from 230 residents of HAT endemic 
regions in DRC, Guinea Conakry, Ivory Coast and Uganda 
(TrypanoGEN consortium, sequences at European Nucleotide 
Archive Study: EGAS00001002602) and 1000 Genomes Project 
data (1000 Genomes Project Consortium et al., 2012) from 
African populations were used to identify sets of unlinked SNP 
(r2<0.5) across IL6, IL4, IL8, IFNG, and HLA-G (Courtin et al., 
2007; Courtin et al., 2013; Ilboudo et al., 2014; Lejon et al., 
2002; Sternberg et al., 2005) (MacLean et al., 2004) using 
the ‘--indep-pairwise 50 5 0.5’ command in plink Plink v1.9 
to select SNP with r2 < 0.5 from sliding windows of 50 SNP 
moving 5 SNP at a time (Chang et al., 2015). A complete 
list of dbSNP identifiers of SNPs selected is shown in Table S1, 
see Extended data (Fataki Asina, 2020).
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Data and statistical analysis
The results were analyzed using Plink V1.9 software 
(Chang et al., 2015; Purcell et al., 2007) and R (R Core Team, 
2008) for viewing. Markers with >40% missing data (--geno 0.4) 
were removed and individuals with >30% (--mind 0.3) missing 
data were removed
Power calculations were undertaken using the genetics analysis 
package (GAP) in R (R Core Team, 2008; Zhao, 2007).
Fisher’s exact test was used to identify associations between 
phenotypes and SNP loci.
The Bonferroni correction was used to correct for multiple 
testing. A p value below 0.05/n was considered statistically 
significant, where n is the number of SNPs in a given 
comparison after quality control.
Results
Quality control of data
In the candidate gene study, 233 DNA samples were genotyped: 
100 active HAT cases, 33 from subjects with latent infections 
and 100 negative controls with a male/female sex ratio of 0.63. 
Data were filtered to remove loci and individuals with exces-
sive missing data. After examining the distribution of the data, 
markers with >40% missing data were removed and individuals 
with >30% missing data were removed. These filters removed 
nine SNP loci, one case, four controls and four seropositives. All 
remaining polymorphisms were in Hardy-Weinberg equilibrium. 
For the validation study, 594 DNA samples were genotyped: 
164 active HAT cases and 430 negative controls with a male/ 
female sex ratio of 0.58. There was no significant difference 
in sex ratio between cases and controls (p=0.56) or between 
discovery and validation groups (p=0.43).
Association analysis in candidate gene study
Data for the three possible comparisons between the three phe-
notypes (cases versus controls; latent infections versus controls; 
and cases versus latent infections) were analysed separately.
Cases and controls. Two SNPs in IL4 (rs2243258 and 
rs2243279) and two in IFNG (rs2430561, rs2069718) had minor 
alleles that appeared to be protective against HAT in the com-
parison between cases and controls (odds ratios <1) before 
Bonferroni correction (Table 1). After Bonferroni correction, 
neither remained significant (p>0.05).
There was no statistically significant difference in allele fre-
quency for CFH, HP, HPR, IL1B, IL12B, IL12RB1, IL6, IL8, IL10, 
TNFA, HLAG, HLAA, MIF, and APOL1 polymorphisms.
Latent infections and controls. The minor alleles of IFNG 
(rs2430561 and rs2069718) SNPs were also protective in the 
comparison between latent infections and controls. The minor 
(T) allele of IL6 (rs2069830) was not found at all in the 29 sub-
jects with latent infections but was found at 7% frequency in the 
controls (Table 2), suggesting that it might be protective against 
seroconversion.
Table 1. Analysis of association between human African trypanosomiasis patients and negative 
control subjects.
SNP Gene CHR BP A1 Case Control A2 P OR SE P (HWE)
rs2243258 IL4 5 132012110 T 0.04 0.12 C 0.003 0.31 0.42 0.16
rs2243279 IL4 5 132016227 A 0.04 0.12 G 0.008 0.34 0.43 0.34
rs2430561 IFNG 12 68552522 A 0.09 0.20 T 0.003 0.42 0.30 1.00
rs2069718 IFNG 12 68550162 G 0.31 0.43 A 0.014 0.59 0.21 0.73
CHR, chromosome number; SNP, dbSNP ID; BP, physical position (base-pair in GRCh37); A1, minor allele name; Case, 
frequency of this allele in cases; Control, frequency of this allele in controls; A2, major allele name; P, exact p-value; 
OR, estimated odds ratio (for A1); SE, standard error of odds ratio; P (HWE): Hardy-Weinberg equilibrium p value for 
unaffected individuals.
Table 2. Association analysis between asymptomatic latent human Africa trypanosomiasis infection 
subjects and negative controls.
SNP Gene CHR BP A1 Latent Control A2 P OR SE P (HWE)
rs2069718 IFNG 12 68550162 G 0.24 0.43 A 0.011 0.41 0.360 1.00
rs2069728 IFNG 12 68547784 T 0.44 0.27 C 0.020 2.08 0.320 1.00
rs2069830 IL6 7 22767137 T 0.00 0.07 C 0.032 0.00 inf 0.05
rs71889624 IL4 5 132013430 DEL 0.00 0.06 CTGA 0.048 0.00 inf 0.03
rs35235644 MIF 22 24237822 C 0.02 0.10 G 0.062 0.18 1.039 0.58
CHR, chromosome number; SNP, dbSNP ID; BP, physical position (base-pair in GRCh37); A1, minor allele name; Latent, 
frequency of this allele in latent infections; Control, frequency of this allele in controls; A2, major allele name; P, exact p-value; 
OR, estimated odds ratio (for A1); SE, standard error of odds ratio; P (HWE): Hardy-Weinberg equilibrium p value for unaffected 
individuals; inf, infinity; DEL, deletion.
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Cases and latent infections. Three SNPs in IL4 (rs2243258, 
rs2243279 and rs71889624) were associated with protec-
tion against progression from latent infection to case (Table 3). 
Two of these were also just as strongly associated with cases and 
controls, despite less than a third of the number of samples of 
latent infections being available. This was a consequence of a 
higher frequency of the minor allele in latent infections than in 
controls. Carriers of the T allele of rs2243258 and those of the 
A allele of rs2243279 of IL4 have a reduced risked of devel-
oping illness; as do carriers of the T allele of rs2069728 of 
IFNG, for asymptomatic carriers in relation to the controls.
The complete absence of the T allele of rs2069830 of IL6 
in latent infections also suggests that this SNP is associated 
with risk of progression to active HAT. None of the associations 
with the latent infections remained significant after Bonferroni 
correction.
Validation study. IL4 and IFNG SNPs that were marginally sig-
nificant in the candidate gene study were not significant in the 
validation study (Table 4).
Discussion
In the candidate gene study, 87 SNPs in 17 candidate 
genes remained after quality control. We found suggestive 
associations with HAT at SNP loci in IL4, IFNG, IL6 and MIF, 
but none of these remained significant after a Bonferroni correc-
tion. It was particularly notable that no association was found 
Table 3. Association analysis between latent infections and cases.
SNP Gene CHR BP A1 Case Latent A2 P OR SE P (HWE)
rs2243279 IL4 5 132016227 A 0.04 0.16 G 0.003 0.21 0.52 0.25
rs2243258 IL4 5 132012110 T 0.04 0.16 C 0.003 0.22 0.52 0.27
rs2069830 IL6 7 22767137 T 0.12 0.00 C 0.004 NA NA 0.33
rs2069728 IFNG 12 68547784 T 0.26 0.44 C 0.019 0.45 0.32 1.00
rs71889624 IL4 5 132013430 DEL 0.07 0.00 CTGA 0.030 NA NA 1.00
rs35235644 MIF 22 24237822 C 0.11 0.02 G 0.044 6.36 1.03 1.00
CHR, chromosome; SNP: dbSNP ID; BP, physical position (base-pair in GRCh37); A1, minor allele; Case, frequency of minor 
allele in cases; Latent, frequency of this allele in latent infections; A2, major allele; P, exact p-value; OR, estimated odds 
ratio (for A1); SE, standard error of odds ratio; P (HWE), Hardy Weinberg equilibrium p value for unaffected individuals; DEL, 
deletion.
Table 4. Validation study.
Source CHR SNP Gene (allele) BP A1 A2 P OR SE P (HWE) Cases Controls
Candidate gene 7 rs1818879 IL6 22772727 A G 0.810 1.07 0.31 0.52 99
Validation study 7 rs1818879 IL6 22772727 A G 0.640 0.89 0.21 0.23 164 430
Candidate gene 5 rs2243258 IL4 132012110 T C 0.003 0.30 0.42 0.12 99
Validation study 5 rs2243258 IL4 132012010 T C 0.330 0.79 0.23 0.40 164 430
Candidate gene 12 rs2430561 IFNG 68552522 A T 0.003 0.41 0.30 0.59 99
Validation study 12 rs2430561 IFNG 68552422 A T 0.810 0.94 0.18 0.70 164 430
Validation study 22 rs71785313 APOL1 (G2) 36662046 2 1 0.010 0.55 0.24 0.63 164 430
Candidate gene 22 rs71785313 APOL1 (G2) 36662046 T A 0.480 0.75 0.40 0.45 99 96
Candidate gene 22 rs73885319 APOL1 (G1) 36661906 G A 0.330 1.27 0.26 1.00 99 96
Validation study 22 rs73885319 APOL1 (G1) 36661806 G A 0.330 0.82 0.19 0.71 164 430
CHR, chromosome; SNP, dbSNP ID; Gene (allele), gene and also allele for APOL1; BP, physical position (base-pair in GRCh37); A1, minor allele; A2, 
major allele; P, exact p-value; OR, estimated odds ratio (for A1); SE, standard error of odds ratio; P (HWE), Hardy Weinberg equilibrium p value for 
unaffected individuals.
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with APOL1 despite the APOL1 protein being lytic to T. brucei 
brucei and some alleles being lytic to T. b. rhodesiense and 
T.b. gambiense in vitro (Genovese et al., 2010). Associations 
have been found with the APOL1 G1 allele in comparisons with 
latent infections in Guinea (Cooper et al., 2017). In that study, 
latent infections had been followed for two years, during which 
time they remained serologically positive but parasitologically 
negative. In our study, latent infections were defined as sero-
logically positive but parasitologically negative at a single visit. 
This different case definition and the small sample size of latent 
infections (n=33) may account for the difference in outcomes. 
Associations have also been found with APOL1 G2 frequen-
cies between cases and controls in T.b.rhodesiense infections in 
Uganda and Malawi (Cooper et al., 2017; Kamoto et al., 2019), 
but another study in Uganda found no association with APOL1 G2. 
Although there is strong evidence for a role for APOL1 in HAT, 
the role of the different alleles in disease response is much 
less clear and may depend on the immunological context.
IL4
The minor alleles of rs2243258 and 2243279 were sugges-
tively associated with protection against development of HAT 
in the case-control comparison and with protection against 
progression from latent infection to HAT, with odds ratios of 
0.28±0.06 in cases versus controls, indicating a potentially large 
effect on the outcome of infection. However, rs2243258 showed 
no sign of association with HAT in the validation study (Table 4).
A similar study in the same Bandundu focus published in 2007 
tested four SNPs in IL4 and found no association with disease, 
but none of those SNPs were the ones with suggestive p values 
in the present study (Courtin et al., 2007). Another TrypanoGEN 
study in Ivory Coast using the same SNP set as in the present 
study found five IL4 SNPs suggestively associated with risk of 
developing a latent infection (uncorrected p values <0.05) 
(Ahouty et al., 2017). None of those five loci were associated with 
disease in our study. If these are genuine associations, two differ-
ent haplotypes with different modes of action may be regulating 
responses to infection in the two countries.
IL4 is an anti-inflammatory cytokine that is more highly 
expressed in late stage or chronic infections in mice and may 
be involved in preventing an excessive inflammatory response, 
causing tissue damage (Bakhiet et al., 1996; Namangala et al., 
2009). However, the only study of IL4 in humans with HAT, 
which we are aware of, found no differences in IL4 levels in the 
cerebrospinal fluid of T. rhodesiense-HAT patients (Maclean 
et al., 2001).
IL6
IL6 (rs2069830, T allele) was suggestively associated with pro-
tection against HAT. This result adds to the evidence from 
previous studies for a role for IL6 in protection against Tbg 
HAT (Bucheton et al., 2011; Sternberg et al., 2005).
A previous study in the same province of Bandundu found a 
significant association at IL6rs2069849 (Courtin et al., 2007). 
This SNP was not included in the present study, but this finding 
supports a role for IL6 variants in the development of HAT. A 
recent study in Guinea found that IL6rs1818879 was associated 
with a lower risk of progressing from latent infection to active 
disease (Kabore et al., 2017) and an Ivorian study found that 
rs62449495 and rs2069830 have a protective effect against devel-
oping active Tbg HAT (Ahouty et al., 2017). The minor allele 
of this last SNP (rs2069830) was also found in the same study 
to be protective against progressing from latent infection to 
cases (Ahouty et al., 2017).
IL6 is an inflammatory protein that plays an important role 
in host immunity, particularly during the acute phase of the 
infection. Its production increases considerably in the late phase 
of infection and decreases dramatically after treatment, suggesting 
that it plays an important role in humans infected with Tbg 
(Lejon et al., 2002).
IFNG
The minor alleles of rs2069718, rs2430561 and rs2069728 were 
associated with protection against progression in Tbg HAT 
in the case versus control, latent infection versus control and 
latent infection versus case comparisons, respectively, although 
the results were not significant after Bonferroni correction. 
Individuals with the T allele of rs2069728 had about half the 
risk of developing HAT in the latent infection versus case com-
parison, as compared to carriers of the C allele. Two of the three 
SNPs within the same gene were tested in an Ivorian 
population and there was no protective effect in a comparison 
of cases versus controls (p>0.05) (Ahouty et al., 2017). A previ-
ous study of cases and controls in the same focus in Bandundu 
(Courtin et al., 2007) revealed no association with HAT at four 
IFNG SNPs but did not include those that were suggestively 
associated in this study. SNP rs2430561 was included in the 
validation study and no evidence of any association was found 
(Table 4). A parallel study in Guinea with the same SNP 
(rs2430561) as the present study also found that IFNG was not 
associated with HAT in both case versus latent infection and 
latent infection versus control comparisons (Kabore et al., 2017). 
Recent studies on humans suggest that IFNG can be associated 
with neurological symptoms in Tbr HAT (Kato et al., 2016) 
but it is not known if this is also true of Tbg HAT. IFNG is 
involved in parasite control in mice (Hertz et al., 1998) and 
recently, its production was found to be elevated above 
background in the plasma of individuals with latent infections 
after stimulation with Tbg lysates but not in controls or cases of 
active HAT (Ilboudo et al., 2016).
Latent infections
It is important to note that more suggestive associations were 
observed in comparisons of latent infections with cases or 
controls than were observed in the case versus control comparison, 
despite the small number of latent infection samples available 
(only 29 after quality control). This may be the most important 
observation of this study and suggests that latent infections 
are a genetically distinct group, as has been found in Guinea 
and Ivory Coast (Ilboudo et al., 2016; Kabore et al., 2017). 
Latent infections might be an important reservoir of infection, 
but their role and significance in the epidemiology of HAT is 
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poorly understood. If people with latent infections have distinct 
genetic characteristics, it may be possible to develop genetic 
approaches to estimating the size of this group.
Validation study
Despite more samples being available in the validation study, 
including 164 cases and 430 controls, IL4 and IFNG SNPs 
were not significantly associated with HAT. Random sample 
variation may account for the difference in outcome of the 
candidate gene and validation studies that used two different 
sets of samples. The negative result of the validation study shows 
how important it is to validate observations from candidate gene 
studies using fresh datasets.
Conclusions
In conclusion, our survey reveals that two SNPs in each of 
IL4 (rs2243258, T allele, and rs2243279, A allele) and IFNG 
(rs2430561, A allele, and rs2069718, G allele) appeared to 
be associated with a low risk of developing symptomatic Tbg 
infection in the Congolese population; however, these associa-
tions were not significant after Bonferroni correction or validation. 
The genetic factors of susceptibility to infection by Tbg in DRC 
were not replicated in other populations, suggesting that genetic 
risk factors may vary according to the population.
Data availability
Underlying data
Raw genotyping data on European Genome-phenome Archive, 
Accession number EGAS00001004365: https://identifiers.org/ 
ega.study:EGAS00001004365.
Access to the data will be granted to life science researchers for 
research purposes only. Users should write to Prof. Dieudonné 
Mumba Ngoyi (mumbadieudonne@yahoo.fr) who will author-
ise the EGA to release the data to the named researchers after 
completion of a data access agreement.
Harvard Dataverse: SNPs in IL4 and IFNG show no protective 
associations with human African trypanosomiasis in the Demo-
cratic Republic of the Congo: a case-control study. https://doi.
org/10.7910/DVN/I7ODO6 (Fataki Asina, 2020).
This project contains the following underlying data:
-    DRC_CAS_CON_Candidate_Validation.xls (complete Plink 
output for the four SNP for used in the validation study)
-    DRC_Revised_Candidate_Gene_Analysis-1.xlsx (Complete 
Plink output for all SNP for the four contrasts: 1) Cases 
v Controls 2) Latent (SERO) v Cases 3) Latent (SERO) 
v Controls 4) Latent (SERO) and Cases v Controls)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
Extended data
Harvard Dataverse: SNPs in IL4 and IFNG show no protective 
associations with human African trypanosomiasis in the Demo-
cratic Republic of the Congo: a case-control study. https://doi.
org/10.7910/DVN/I7ODO6 (Fataki Asina, 2020).
This project contains the following extended data:
-    SupplementaryDataTable_S1.txt (Table S1, SNPs genotyped 
in this study including rs id and co-ordinates in GRCh37 
genome build)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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